Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain
- PMID: 11607046
- PMCID: PMC6494119
- DOI: 10.1111/j.1527-3458.2001.tb00202.x
Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain
Abstract
Hundreds of millions of people now die over the age of 80 years primarily due to twentieth century progress in hygiene, chemotherapy, and immunology. With a longer average lifespan, the need to improve quality of life during the latter decades is more compelling. "Aging--The Epidemic of the New Millenium," a recent international conference (Monte Carlo, June 17-18, 2000), showed with peculiar clarity that a safe and efficient drug strategy to slow the age-related decay of brain performance is still missing. This review summarizes the physiologic and pharmacologic arguments in favor of a peculiar lifelong prophylactic medication with reasonable chances to keep in check brain aging and decrease the precipitation of age-related neurological diseases.
Similar articles
-
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).Mol Psychiatry. 2016 Nov;21(11):1499-1503. doi: 10.1038/mp.2016.127. Epub 2016 Aug 2. Mol Psychiatry. 2016. PMID: 27480491 Review.
-
Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.Bioorg Med Chem. 2001 May;9(5):1197-212. doi: 10.1016/s0968-0896(01)00002-5. Bioorg Med Chem. 2001. PMID: 11377178
-
(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.Br J Pharmacol. 1999 Dec;128(8):1723-32. doi: 10.1038/sj.bjp.0702995. Br J Pharmacol. 1999. PMID: 10588928 Free PMC article.
-
The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.Neuropsychopharmacol Hung. 2004 Dec;6(4):210-20. Neuropsychopharmacol Hung. 2004. PMID: 15825677 Review.
-
A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.Life Sci. 2003 Apr 25;72(23):2641-8. doi: 10.1016/s0024-3205(03)00174-7. Life Sci. 2003. PMID: 12672509
Cited by
-
Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives.Neurochem Res. 2003 Aug;28(8):1275-97. doi: 10.1023/a:1024224311289. Neurochem Res. 2003. PMID: 12834268 Review.
-
Expression of neurotrophic factor genes by human adipose stem cells post-induction by deprenyl.Anat Cell Biol. 2021 Mar 31;54(1):74-82. doi: 10.5115/acb.19.229. Anat Cell Biol. 2021. PMID: 33526752 Free PMC article.
-
Therapeutic Potential of Dopamine and Related Drugs as Anti-Inflammatories and Antioxidants in Neuronal and Non-Neuronal Pathologies.Pharmaceutics. 2023 Feb 18;15(2):693. doi: 10.3390/pharmaceutics15020693. Pharmaceutics. 2023. PMID: 36840015 Free PMC article. Review.
-
Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum.Int J Mol Sci. 2022 Aug 1;23(15):8543. doi: 10.3390/ijms23158543. Int J Mol Sci. 2022. PMID: 35955676 Free PMC article.
-
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).Mol Psychiatry. 2016 Nov;21(11):1499-1503. doi: 10.1038/mp.2016.127. Epub 2016 Aug 2. Mol Psychiatry. 2016. PMID: 27480491 Review.
References
-
- Agnoli A, Fabbrini G, Fioravanti M, Martucci N. CBF and cognitive evaluation of Alzheimer‐type patients before and after MAO‐B treatment: A pilot study. Eur Neuropsychopharmacol 1992;2:31–35. - PubMed
-
- Allain H, Gougnard J, Naukirek HC. Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMP). Acta Neurol Scand 1991;136:73–78. - PubMed
-
- Archer JR, Harrison DE. L‐Deprenyl treatment in aged mice slightly increases lifespans and greatly reduces fecundity by aged males. J Gerontol Sci 1996;13A:B448–B453. - PubMed
-
- Birkmayer W, Hornykiewicz O. Der L‐Dioxyphenyl‐alanin‐Effekt beim Parkinson Syndrom des Menschen. Arch Psychiat Nervenkrh 1962;203:560–564.
-
- Birkmayer W, Riederer P. Parkinson's Disease. Biochemistry, Clinical Pathology and Treatment. New York : Springer‐Verlag, 1983:1–194.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical